Phlogo

Phlogo is a biotechnology company dedicated to pioneering new treatments for chronic inflammatory conditions by targeting the fundamental mechanisms of innate immunity. Founded by a trio of distinguished scientists—Richard Flavell, Ruslan Medzhitov, and Eran Elinav—the company translates decades of breakthrough research into a pipeline of therapeutic candidates. Phlogo's approach focuses on the concept of "phlogosis," aiming to resolve inflammation at its source rather than merely suppressing symptoms. The company is currently in the pre-clinical stage, supported by leading venture capital firms like 8VC to advance its mission of transforming patient care in immunology. By leveraging proprietary insights into the molecular drivers of disease, Phlogo aims to develop precision medicines for a wide range of autoimmune and inflammatory disorders.